Albergoni, Matteo
Pagani, Elisabetta
Preziosa, Paolo
Meani, Alessandro
Margoni, Monica
Rocca, Maria A.
Filippi, Massimo http://orcid.org/0000-0002-5485-0479
Funding for this research was provided by:
Ministero della Salute (GR-2019–12369599)
Article History
Received: 13 December 2023
Revised: 1 February 2024
Accepted: 25 February 2024
First Online: 20 March 2024
Declarations
:
: M. Albergoni has nothing to disclose; E. Pagani has nothing to disclose; P. Preziosa received speaker honoraria from Roche, Biogen, Novartis, Merck Serono, Bristol Myers Squibb, Genzyme, Horizon and Sanofi, he has received research support from Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla; A. Meani has nothing to disclose; M.A. Rocca received consulting fees from Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche; and speaker honoraria from AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. She receives research support from the MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. She is Associate Editor for <i>Multiple Sclerosis and Related Disorders</i>. M. Filippi is Editor-in-Chief of the <i>Journal of Neurology</i>, Associate Editor of <i>Human Brain Mapping</i>, <i>Neurological Sciences,</i> and <i>Radiology</i>; received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi; speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
: Approval was received from the institutional ethical standards committee on human experimentation of IRCCS Ospedale San Raffaele (Protocol number 59/INT/2015). Written informed consent was obtained from all subjects prior to study participation according to the Declaration of Helsinki.